Background: Biosynthesis and metabolism of nicotinic acid adenine dinucleotide phosphate (NAADP) are unclear.
Nicotinic acid adenine dinucleotide phosphate (NAADP) is a ubiquitous second messenger providing a Ca
2+ trigger in a wide range of cell types. However, its metabolism is not well understood. Here we demonstrate presence of endogenous NAADP in HeLa cells. CD38, a promiscuous enzyme discussed to be involved in NAADP metabolism, was not detectable in HeLa cells. In cell free extracts of HeLa cells NAADP was degraded to nicotinic acid adenine dinucleotide (NAAD). The enzyme was enriched in membranes (10,000 x g pellet) and displayed typical characteristics of alkaline phosphatase (AP), e.g. pH optimum at 8 to 9 and sensitivity to the inhibitors L-homo-arginine and L-leucine. Importantly, physiological concentrations of NAADP (50 to 100 nM) were degraded to NAAD. Expression of AP isozymes was analyzed in HeLa cells. Together with inhibitor studies, the placental AP isoform emerged as best candidate for NAADP degradation in HeLa cells. In contrast to HeLa cells, Jurkat T cells or HEK293 cells did not express any AP isozymes and did not display any NAADP 2´-phosphatase activity. Finally, the placental AP isoform was expressed heterologously in HEK293 cells resulting in reconstitution of NAADP 2´-phosphatase activity in cell free extracts. Taken together, we provide evidence for AP as metabolizing enzyme of NAADP in cells that do not express CD38.
Nicotinic acid adenine dinucleotide phosphate (NAADP) is a ubiquitous second messenger involved in Ca
2+ signaling in a wide range of cell types (reviewed in ref. 1) . NAADP acts at low nanomolar concentrations and is produced endogenously upon stimulation by several agonists (2) (3) (4) (5) . The intracellular target of NAADP is still unclear since several ion channels have been proposed to respond to NAADP, e.g. ryanodine receptors (RyR; refs. 6,7), TRP mucolipin 1 (8) , and two-pore channels channels (TPC) (9) (10) (11) . The recent identification of small molecular weight soluble proteins specifically binding NAADP along with lack of direct labeling of TPCs (12) is in favor of a model in which such soluble NAADP binding proteins mediate the effect of NAADP at different Ca 2+ channels, as proposed originally by Gerasimenko and colleagues (13) .
Similar to its unclear mechanism of action, metabolism of NAADP is poorly understood. Though NAADP can be formed in vitro by CD38 via the base exchange mechanism, others and we demonstrated that knock out or gene silencing of CD38 either did not affect or even increased endogenous NAADP levels in cells and tissues (14, 15) . However, the situation is more complex since in some cell types from CD38 knock out mice, e.g. pancreatic acinar cells, NAADP levels were indeed lower as compared to wild type mice (16) . Interestingly, increased NAADP contents in immunologically relevant tissues from CD38 knock out mice, e.g. spleen and thymus, indicate a role for CD38 in NAADP degradation. Indeed, others and we have shown that metabolism of NAADP to 2´-phospho-adenosine diphosphoribose (2´-P-ADPR) takes place under physiological conditions in vitro (14, 17) .
In the present study we investigated the degradation of NAADP in HeLa cells. Expression of CD38 was not detectable in these cells. The degradation product was different from the product obtained in CD38 expressing cells, 2´-P-ADPR and was identified by HPLC as nicotinic acid adenine dinucleotide (NAAD). The NAADP phosphatase activity was characterized, identified and heterologous expression restored its activity.
EXPERIMENTAL PROCEDURES
Reagents.NAADP and 1,N 6 -etheno-nucleotides were obtained from Biolog (Bremen, Germany). Other compounds and chemicals were purchased from Sigma-Aldrich (Munich, Germany) Cell Culture. Jurkat T lymphocytes (subclone JMP) were cultured in RPMI 1640 medium supplemented with Glutamax, HEPES (25 mM), 7.5% (v/v) newborn calf serum, 100 U/ml penicillin and 100 µg/ml streptomycin. HeLa and HEK293 cells were cultured in DMEM medium supplemented with Glutamax, 10 % (v/v) fetal calf serum, 100 U/ml penicillin and 100 µg/ml streptomycin.
Analysis of endogenous NAADP. Endogenous NAADP was extracted and quantified by the enzymatic NAADP cycling assay (5) . Briefly, 2*10 8 HeLa cells were divided into identical twin samples and centrifuged (500xg, 5 min). One part was spiked with 15 pmol NAADP to be able to calculate recovery. Then, cells pellets were resuspended in 1 ml ice-cold trichloroacetic acid (20%, w/v) and frozen in liquid N 2 . After two freeze-thaw cycles, samples were centrifuged (4400xg, 10 min, 4°C). The supernatant was neutralized by extraction with watersaturated diethyl ether. Samples were purified by anion exchange chromatography. NAADP was quantified by the enzymatic NAADP cycling assay (5) . Increase in fluorescence was measured at λ Ex = 530 nm and λ Em = 590 nm on a fluorescence micro plate reader (Infinite M200 with Software i-control, Tecan, Grödig, Austria). Mean recovery of NAADP in control samples was 66%. Data were subjected to Grubbs outlier test (significance level < 0.01) and then tested using one-sample t-test vs the hypothetical value 0.
Analysis of mRNA.Total RNA was extracted from 1*10 7 cells using the RNeasy Mini Kit with oncolumn DNase digest (Qiagen, Hilden, Germany). RT-PCR was performed with the Titan One Tube RT-PCR Kit (Roche, Mannheim, Germany) according to the manufacturer's protocol. Primers for the amplification are listed in Tab. 1. Nested PCR was performed with diluted product of the RT-PCR, primers (Tab. 1) and Taq-DNA-Polymerase (Fermentas, St. Leon-Rot, Germany).
Preparation of subcellular fractions. Subcellular fractions were obtained by differential centrifugation as previously described (14, 18) . Briefly, cells were lysed with a Potter Elvehejm-homogenizer, cell debris and nuclei were discarded. Membrane protein fractions were obtained as pellet after 10,000xg centrifugation (P10 membranes) or after 100,000xg centrifugation (P100 membranes) and dissolved in buffer containing 140 mM NaCl, 20 mM HEPES and protease inhibitor complete EGTA free (Roche, Mannheim, Germany) at pH 7.4. Supernatant after 100,000xg centrifugation was termed S100.
Western blot analysis of CD38. For determination of CD38 expression, membrane protein P10 (15 µg) was separated under non reducing conditions by SDS-PAGE using a 12.5% gel and transferred onto a PVDF membrane. One part of the membrane was incubated with anti-CD38 antibody AT1 (1 µg/ml, 1 h; Santa Cruz Biotechnology, Heidelberg, Germany), the second part was incubated with antiHsc70 antibody (0.04 µg/µl, 1 h, Santa Cruz Biotechnology, Heidelberg, Germany) as loading control. Then the membranes were incubated with the secondary antibody (goat anti-mouse horseradish peroxidase conjugate, 0.2 µg/ml, 1 h, Dianova, Hamburg, Germany). Membranes were incubated for 1 min with ECL solution (Amersham Biosciences; Freiburg, Germany). Chemiluminescence was detected with Intelligent Dark Box, CAS 3000 (FujiFilm, Tokyo, Japan).
Western blot analysis of alkaline phosphatase.
To analyze the expression of the different isozymes of alkaline phosphatase, 15 µg membrane protein (P10) were separated under reducing conditions by SDS-PAGE using a 10% gel and transferred onto a PVDFmembrane. One part of the membrane was incubated with antibody specific for each isozyme for 1 h (mouse anti human GCAP, 2.5µg/ml, AbdSerotec, Düsseldorf, Germany; rabbit anti human PLAP, 1:800, Abcam, Cambridge, UK; mouse anti human IAP, 0.6µg/ml, Abcam, Cambridge, UK; rabbit anti human TNAP, 0.6µg/ml, Abcam, Cambridge, UK), the other part was incubated with mouse anti-human ß-actin antibody (1:1200, Sigma-Aldrich, Darmstadt, Germany) as loading control. Then the membranes were incubated for 1h with the corresponding HRPconjugated secondary antibody (goat anti-mouse, 1:2500 or goat ant-rabbit, 1: 5000; Dianova, Hamburg, Germany). After incubation with ECL solution (Amersham Biosciences; Freiburg, Germany) for 1 min, chemiluminescence was detected with Intelligent Dark Box, CAS 3000 (FujiFilm, Tokyo, Japan).
Analysis of NAD-glycohydrolase activity. NADglycohydrolase activity of CD38 was tested with a fluorescence assay. Membrane protein P10 (100 µg/ml) of Jurkat and HeLa cells was incubated with 100 µM 1,N 6 -etheno-NAD for 30 min. NADglycohydrolase converts the weakly fluorescent 1,N 6 -etheno-NAD into highly fluorescent 1,N 6 -etheno-ADPR. Increase in fluorescence was measured at λ Ex = 300 nm and λ Em = 410 nm on a fluorescence micro plate reader (Infinite M200 with Software i-control, Tecan, Grödig, Austria).
Determination of phosphate release with malachite green. P10 membrane protein (1 µg/ml) of HeLa cells were incubated with 10 µM NAADP in TEA buffer (50 mM triethanolamine, 2 mM MgCl 2 , pH 8.0) for 30 min. Release of free phosphate was then detected by complexation with molybdate and malachite green (Malachite Green Phosphate Assay Kit, BioAssay Systems, Hayward, USA) according to manufacturer's protocol. Absorption was measured at λ = 600 nm on a micro plate reader (Infinite M200 with Software i-control, Tecan, Grödig, Austria).
Determination of phosphatase activity with pNPP. P10 membrane protein (1 µg/ml) of HeLa cells were incubated with 5.5 mM para-nitrophenyl phosphate (pNPP) in DEA buffer (1 M diethanolamine, 1 mM MgCl 2 , pH 9.8) for 20 min. Alkaline phosphatase dephosphorylates the colorless substrate pNPP to yellow para-nitrophenol. Absorption of the dephosphorylated product was measured at λ = 405 nm on a micro plate reader (Infinite M200 with Software i-control, Tecan, Grödig, Austria).
Determination of endogenous intracellular NAADP 2´-phosphatase activity in HeLa cells. HeLa cells
were detached, washed twice with PBS, resuspended either in PBS (140 mM NaCl, 3 mM KCl, 8 mM Na 2 HPO 4 , 1.5mM KH 2 PO 4 , pH 7.4) or PBS supplemented with 1 mg/ml bromelain (SigmaAldrich) and incubated for 30 min at 37°C. Subsequently cells from both conditions (± bromelain) were washed twice with assay buffer (140 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 1 mM CaCl 2 , 20 mM HEPES, 1 mM NaH 2 PO 4 , 5.5 mM glucose, pH 7.4), resuspended either in assay buffer or in assay buffer containing 60 µg/ml saponin and incubated for 5 min at 37°C. Afterwards cells were again washed twice and resuspended in assay buffer. Protein content was determined using BioRad protein assay. The different cell preparations were then incubated with 100 µM NAADP for 1, 3 and 10 min. Reaction was stopped by addition of ice-cold trichloroacetic acid (TCA) to a final concentration of 5% (v/v). TCA was removed by extraction with water-saturated diethyl ether. After neutralization of the samples by addition of phosphate buffer and removal of traces of residual TCA in a centrifugal evaporator, samples were analyzed for NAAD and NAADP content by HPLC.
HPLC analysis of nucleotides. Reaction products were filtered through a 10 kDa cut-off filter (Microcon, Millipore, Billerica, MA, USA), diluted in elution buffer containing 20 mM KH 2 PO 4 and 5 mM tetrabutylammonium dihydrogen phosphate at pH 6 and analyzed by ion pair RP-HPLC performed on a 250 x 4.6 mm C18-5µ HYPURITY ADVANCE column (Thermo Fisher Scientific, Schwerte, Germany) or Multohyp BDS (Chromatographie Service, Langerwehe) equipped with a 10 x 4 mm guard cartridge filled with the same material (Thermo Fisher Scientific, Schwerte, Germany or Chromatographie Service, Langerwehe, Germany). Nucleotides were eluted with a nonlinear gradient with elution buffer and increasing amounts of methanol. Analysis of metabolism of 1,N 6 -etheno-NAD was performed at 25°C at a flow rate of 1 ml/min with the following gradient (% methanol): 0 min (0) Nucleotides were detected by UV absorption at λ = 260 nm with a diode array detector (1200 series, Agilent Technologies, Böblingen, Germany) while fluorescent nucleotides were detected at λ Ex = 300 nm and λ Em = 410 nm with a fluorescence detector (1200 series, Agilent Technologies, Böblingen, Germany). Product peaks were analyzed with ChemStation Software (Agilent technologies, Böblingen, Germany). Quantification was performed with external standards.
Recombinant expression of alkaline phosphatase in HEK293 cells. cDNA of placental alkaline phosphatase (PLAP) was obtained from imaGenes (Berlin, Germany) and cloned into the vector pIRES2-EGFP (BD Clontech, Heidelberg, Germany) resulting in the expression vector termed pIRES2-EGFP-PLAP. HEK293 cells were transfected at approximately 80% confluency with lipofectamine LTX (life technologies, Darmstadt, Germany) according to manufacturer's protocol. Expression of EGFP was verified 24 h after transfection by fluorescence microscopy. Alkaline phosphatase activity was analyzed 24 h post transfection.
RESULTS
Analysis of endogenous NAADP levels in wt HeLa cells using an enzymatic cycling assay revealed basal NAADP concentration of 9.9 ± 2.2 nM (mean ± SEM, n=13, p=0.0007 vs hypothetical value 0; see also Suppl. Fig. 1 ). Recently, CD38 has been implicated in both NAADP formation (17, 19) and degradation (14, 17) . However, expression of CD38, as analyzed at the mRNA and protein level (Fig.  1A,B) , was not detectable in HeLa cells. In comparison to Jurkat T cells that do express CD38 (Fig. 1A,B) , in protein extracts of HeLa cells only minor degradation of 1,N 6 -etheno-NAD was observed (Fig. 1C) . HPLC analysis of the reaction products revealed negligible pyrophosphatase activity and lack of detectable NAD glycohydrolase activity in Hela cells. When NAADP was incubated with either membranes or cytosolic protein extracts from HeLa cells, the major reaction product was identified as NAAD indicating a phosphatase activity degrading NAADP ( Fig. 2A) . This enzyme activity was prominent in P10 membrane fraction and weakly also in P100 membranes and the cytosolic fraction S100 (Fig. 2) . The NAADP 2´-phosphatase activity revealed a pH optimum between 8 and 9 (Fig. 3A) . Different buffers used at the same pH showed only minor effect on NAAD formation (Suppl. Fig. 2 ). Michaelis-Menten kinetics resulted in K m = 37 µM. The specific activity in P10 membranes was 0.8 µmol/mg/min. Since endogenous NAADP levels are in the range of approximately 10 to 100 nM (5, 20) , a K m of 37 µM appeared somewhat large and raised the question whether this enzymatic activity might be of physiological relevance. Thus, in the next set of experiments, physiological concentrations of NAADP were used as substrate. In fact, incubation of NAADP concentrations as low as 50 nM with P10 membranes from HeLa cells resulted in NAAD formation (Fig. 4A,B) . Furthermore, even at pH 7.2 the 2´-phosphatase reaction was observed; here the fluorescent 1,N 6 -etheno-NAADP was used as substrate and metabolism to 1,N 6 -etheno-NAAD was monitored by HPLC and fluorescence detection (Fig.  5) . The second metabolic product observed at pH 9 only, 1,N 6 -etheno-ADPR also was formed in the absence of protein, obviously due to non-enzymatic degradation of 1,N 6 -etheno-NAADP via 1,N 6 -etheno-2´-phospho-ADPR, visible as shoulder of the 1,N 6 -etheno-NAADP peak. Since degradation of NAADP to NAAD preferentially occurred at alkaline pH, alkaline phophatase (AP) appeared a suitable candiate for the NAADP 2'-phosphatase. Thus, expression of isozymes of AP was analyzed in HeLa cells. On both mRNA and protein level the AP isozymes PLAP, intestinal alkaline phospatase (IAP) and tissuenonspecific alkaline phospatase (TNAP) were detected (Fig. 6A,B) . To assess which isoform is responsible for the degradation of NAADP, isoform-specific inhibitors were tested. L-Homo-arginine has been reported to mainly inhibit TNAP and has very little effect on the other isoforms (21) . In contrast, L-phenylalanine especially inhibits the tissue specific isoforms and shows little impact on TNAP (22) . The third inhibitor, L-leucine, does not affect TNAP activity, but strongly reduces activity of PLAP and GCAP 21,23). Using the non-specific AP substrate paranitrophenyl phosphate (pNPP), degradation was mainly sensitive to L-homo-arginine and L-leucine confirming expression of TNAP and PLAP in HeLa cells (Fig. 6C) . Interestingly, L-homo-arginine did not inhibit degradation of NAADP by AP suggesting that TNAP is not involved in this process (Fig. 6D) . However, since L-leucine was the best inhibitor of NAADP degradation to NAAD (Fig. 6D ) and since GCAP was not expressed in HeLa cells (Fig. 6B) , PLAP appeared the best candidate for the enzymatic activity observed. HeLa cells are known for their high expression of PLAP (22, 24, 25) . Furthermore, the enzymatic characteristics observed in HeLa cells in our study indicate that PLAP is the most prominent isoform in these cells. Phosphodiesterase activity has been reported for TNAP, but not for PLAP (26, 27) . Importantly, in the present study phosphodiesterase activity using 3´,5´-cyclic AMP as substrate was not detected in HeLa cells (data not shown). In addition, IAP and TNAP show lower specific activity in the presence of highly phosphorylated substrates (28, 29) . On the contrary, no correlation between the degree of phosphorylation and phosphatase activity was seen with PLAP (30) . In the present study the degree of substrate phosphorylation had no influence on the phosphatase activity (data not shown) indicating that the observed NAADP 2´-phosphatase activity is mainly due to the expression of PLAP. In Jurkat T cells NAADP was metabolized to 2´-P-ADPR (14) whereas degradation of NAADP to NAAD was never observed in those cells (Fig. 7 C,D) . Consistently, expression of the AP isozymes was not detectable in Jurkat T cells (Fig. 7 A,B) . Taken together our data indicate specific degradation of physiological concentrations of NAADP to NAAD by AP, likely by the isozyme PLAP. To confirm these results we aimed at recombinant expression of AP in a cell in which expression of endogenous AP is not detectable. Thus, HEK293 cells were characterized towards expression and enzymatic activity of AP isozymes (Fig. 8) . No endogenous expression of any of the AP isozymes (Fig. 8 A,B) and no AP activity was detected (Fig. 8 C,D) . Thus, HEK293 cells appeared a suitable cell system to express AP and to analyze protein extracts for recombinant AP activity towards the substrate NAADP. Indeed, expression of PLAP in HEK293 cells resulted in dephosphorylation of NAADP to NAAD while no such enzymatic activity was observed in EGFP-transfected HEK293 cells (Fig. 9 ).
AP is localized on the cell surface as a GPI-anchored ectoenzyme (31), but expression in intracellular membranes, e.g. ER, Golgi, lysosomes and mitochondria (32-36) has been described. Interestingly, cytosolic AP enzyme activity was detected in saponin-permeabilized HeLa cells (35) indicating correct localization for potential involvement in cytosolic signal transduction. To test for intracellular NAADP 2´-phosphatase activity in HeLa cells, bromelain was used to proteolytically cleave surface protein. NAADP 2´-phosphatase activity decreased under such conditions (Fig. 10) . Subsequent permeabilization by saponin in the absence of bromelain significantly increased NAADP 2´-phosphatase activity (Fig. 10) confirming intracellular localization of PLAP, as described for AP 31 years ago (35) . Similar results were obtained in HEK293 cells overexpressing PLAP; however, PLAP was removed from the cell surface using phosphoinositide-specific phospholipase C instead of bromelain (data not shown).
DISCUSSION
In the current study we demonstrate (i) the presence of endogenous NAADP in the HeLa cell line, a cell type in which expression of CD38 is not detectable, (ii) degradation of NAADP to NAAD in HeLa cell extracts, (iii) identification of alkaline phosphatase (AP) as NAADP degrading enzyme, and (iv) intracellular localization of the NAADP degrading enzyme. Although NAADP appears as a very important and probably ubiquitous second messenger, several aspects of its metabolism are unknown. Though the base-exchange reaction, catalyzed mainly, if not exclusively, by CD38 is the only reaction shown in vitro to produce NAADP (19) , a growing number of reports suggests that endogenous NAADP is detected in cells or tissues even when the gene for CD38 is silenced, e.g. using an shRNA approach, or in CD38 knock-out mice (14, 15 . However, the presence of endogenous NAADP suggests that there must be an enzymatic activity for formation of NAADP other than CD38. The fact that neither kinase nor deamidase activity has been detectable so far indicates a more complex situation than hitherto acknowledged. It might well be that coenzyme(s) or co-subtrate(s) necessary for these reactions have not been added in the right way in the in vitro assays carried out so far. Regarding degradation of NAADP our enzymatic assays combined with HPLC analysis of reaction products revealed 2 main reactions: (i) release of nicotinic acid to produce 2´-P-ADPR by CD38, or (ii) release of inorganic phosphate to generate NAAD. The latter reaction was catalyzed by the placental alkaline phospatase isozyme (PLAP) in cell extracts from HeLa cells. An involvement of AP enzyme activity has not yet been implicated in NAADP metabolism, but a NAADP phosphatase activity from brain membranes was described (37) . This NAADP 2´-phosphatase was characterized by a K m = 7 µM, a specific activity of approx. 160 pmol/min/mg protein, and a dependency on free [Ca 2+ ]. Free [Ca 2+ ] ≥ 0.1 µM increased enzymatic activity substantially (37) . Interestingly, Berridge et al. (37) have compared their NAADP 2´-phosphatase activity to commercially available alkaline phosphatase activity, but instead of analyzing any pH-dependency rather focused on the Ca 2+ dependency of their enzymatic activity (37 (37) is an AP, remains to be investigated. The present study aimed far beyond characterization of the enzyme activity. In fact, we used the characterization, e.g. pH optimum between 8 and 9 and specific inhibition by L-leucine, to narrow down a suitable candidate enzyme. Most importantly, though the K M for NAADP was in the micromolar range, we demonstrated sufficient 2´-phosphatase activity also for NAADP concentrations at 50 and 100 nM, even at pH 7.2. Finally, expression analysis of AP isozymes in HeLa, Jurkat, and HEK293 cells allowed heterologous expression of the AP isozyme PLAP in HEK cells resulting in NAADP degradation to NAAD in cell extracts. Is there anything known about an involvement of PLAP in (NAADP) signaling? In vitro, PLAP is a promiscous enzyme that degrades different adenine and uridine nucleotides, glucose 6--phosphate, ß--glycerophosphate, and others (39) . Phosphatidates with long fatty acid chains have been descibed as substrates, too (40) . However, the physiological substrate of AP isozymes has remained unclear. In the present study, we present evidence that endogenous, very small NAADP concentrations are degraded by AP and that AP might be involved in this process under physiological conditions. However, PLAP is expressed on the cell surface as a GPI--anchored enzyme (31) . Thus, in this sense PLAP resembles the ectoenzyme CD38 that can be detected on the surface of many cell types (reviewed in 41). This "topological paradox" has been solved for CD38 and its ADP-ribosyl cyclase enzymatic activity since De Flora and colleagues demonstrated transport pathways for both the substrate NAD via connexin 43 and also for the product cADPR via nucleoside transporters, respectively (42) (43) (44) . For AP, expression in the cytosol and in intracellular membranes was described in earlier publications (32--36) . Here, we successfully reproduced an increase of AP activity upon permeabilization of HeLa cells using NAADP as substrate confirming correct localization for potential involvement in cytosolic signal transduction, as reported earlier (35) . Taken together, we present the AP isozyme PLAP as a candidate enzyme for degradation of NAADP to NAAD. In cells that lack CD38, like the HeLa cell line, this degradation pathway may be important to terminate NAADP responses. Primers used for RT-PCR and nested PCR. Primers specific for alkaline phosphatase isozymes were adapted from Schär et al. (45) . Alkaline phosphatase was detected with antibodies specific for the different isoenzymes. Alkaline phosphatase is highly glycosylated and therefore the apparent molecular weight is larger than the predicted molecular weight (57 kDa). Isoform-specific inhibition: (C) Membrane protein of HeLa cells (1 µg/ml) was preincubated with 10 mM inhibitor for 10 min on ice. Then 5.5 mM para-nitrophenyl phosphate (pNPP) were added and incubated for 20 min. Absorption of the dephosphorylated reaction product was measured at λ = 405 nm. (D) Membrane protein of HeLa cells (1 µg/ml) was preincubated with 10 mM inhibitor for 10 min on ice. Then, 10 µM NAADP were added and incubated for 30 min. Release of phosphate was then assessed with the malachite green assay. Data shown are mean values ± SD (n = 4 -8); *** p < 0.001 ANOVA. 
